Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors

Type of Cancer
Leukemia

Phase

Division (Location)

Study ID

NCT#

Brief Description
Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.